Showing results (121-130 of 173) with videos related to

Sort By:
Pageof 18
Cancer|July 21, 1998
Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative GroupW Kern, G Behre, T Rudolf, et al.
Seminars in Oncology|June 1, 1987
High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemiaW Hiddemann, H Kreutzmann, K Straif, et al.
Haematology and Blood Transfusion|January 1, 1990
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Seminars in Oncology|February 1, 1997
Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effectsT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia|October 10, 1998
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative GroupW Kern, J Braess, A Grote-Metke, et al.
Blood|September 1, 1991
Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapseT Büchner, W Hiddemann, M Koenigsmann, et al.
Leukemia|January 1, 1992
Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCGT Büchner, W Hiddemann, B Wörmann, et al.
Leukemia|July 17, 1998
Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonW Kern, C Aul, G Maschmeyer, et al.
Annals of Hematology|October 31, 1998
Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukemia. German AML Cooperative GroupW Kern, C Aul, G Maschmeyer, et al.
Pathology, Research and Practice|January 1, 1985
Differential pattern of DNA-aneuploidy in human malignanciesT Büchner, W Hiddemann, B Wörmann, et al.
Pageof 18